Global Therapeutic Drug Monitoring

Therapeutic Drug Monitoring Comprehensive Study by Type (Consumable, Equipment (Immunoassay analyzer)), Application (Hospitals (Clinical Pharmacology departments), Pathological labs, Research and Academic Institutions, Pharmaceutical and Biotech firms), Therapeutic Areas (Alimentary Tract, Hematological Disease, Others), Technology (Fluorescence Immunoassay, Radioimmunoassay, GCMS), Class of drugs (Anti-epileptics, Antibiotics, Immunosuppressants, Anti-arrhythmics) Players and Region - Global Market Outlook to 2030

Therapeutic Drug Monitoring Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
The increasing ageing population with better health care services, increased government and private sector participation in therapeutic drug monitoring markets, growth in drug profiling, rising demand for genetic testing will help to boost the global Therapeutic Drug Monitoring market. Therapeutic drug monitoring (TDM) utilizes the principle that the clinical response of a drug is directly related to its concentration in blood and hence monitoring is carried out and to support the management of patients receiving certain drugs. The central goal of TDM is to use drug concentration to manage drug regimens to optimize therapy. The target group consisted of about 30 scientists who work in the Biochemistry, Toxicology and Microbiology laboratories at the Manchester Royal Infirmary, and who carry out TDM on a regular basis.

AttributesDetails
Study Period2018-2030
Base Year2023
High Growth MarketAsia Pacific
UnitValue (USD Million)
Key Companies ProfiledAbbott Laboratories (United States), Hoffmann-La Roche (Switzerland), Siemens Healthineers (Germany), Thermo Fisher Scientific (United States), Danaher Corporation (United States), Bio-Rad Laboratories (United States), Biomérieux (France), Bühlmann Laboratories (Switzerland), Sekisui Medical (Japan) and Randox Laboratories (United Kingdom)


This growth is primarily driven by Increasing Use of Therapeutic Drug Monitoring in traditional anticancer therapies and The introduction of novel devices with marked technological advancements facilitates rapid throughput operations.

Globally, a noticeable market trend is evident Upsurging demand for Personalized medicine and advanced technologies such as assay performance and drug monitoring The Diseases & Therapeutic Areas sector in the North America region has been increasing at a sustainable rate, and further growth is expected to be witnessed over the forecast period, owing to the robust investments and expansion in production facilities in the region. Major Players, such as Abbott Laboratories (United States), Hoffmann-La Roche (Switzerland), Siemens Healthineers (Germany), Thermo Fisher Scientific (United States), Danaher Corporation (United States), Bio-Rad Laboratories (United States), Biomérieux (France), Bühlmann Laboratories (Switzerland), Sekisui Medical (Japan) and Randox Laboratories (United Kingdom), etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years. The key players are introducing new-generation, clinically-effective drug monitoring devices that are portable and miniaturized so as to gain a competitive edge in the market.

Influencing Trend:
Upsurging demand for Personalized medicine and advanced technologies such as assay performance and drug monitoring and Increasing Number of organ transplant procedures

Market Growth Drivers:
Increasing Use of Therapeutic Drug Monitoring in traditional anticancer therapies and The introduction of novel devices with marked technological advancements facilitates rapid throughput operations

Challenges:
Operational barriers faced in conducting TDM tests

Restraints:
The reluctance of small hospitals to offer TDM services

Opportunities:
Monitoring of biosimilars in autoimmune diseases and The Growing Healthcare Infrastructure across the Developing Countries

AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts but also includes significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints in Therapeutic Drug Monitoring Market
- Analysis about New Entrants in Therapeutic Drug Monitoring Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis
- An Unbiased Perspective towards Market Performance & Indicators

Against this Challenging Backdrop, Therapeutic Drug Monitoring Study Sheds Light on
— The Therapeutic Drug Monitoring Market status quo and key characteristics. To end this, Analysts at AMA organize and took surveys of the Therapeutic Drug Monitoring industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Therapeutic Drug Monitoring industry is heading and what are the top priorities. Insights are drawn from financial analysis, surveys, and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold the value they currently claim or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • Consumable
  • Equipment [Immunoassay analyzer]
By Application
  • Hospitals (Clinical Pharmacology departments)
  • Pathological labs
  • Research and Academic Institutions
  • Pharmaceutical and Biotech firms
By Therapeutic Areas
  • Alimentary Tract
  • Hematological Disease
  • Others

By Technology
  • Fluorescence Immunoassay
  • Radioimmunoassay
  • GCMS

By Class of drugs
  • Anti-epileptics
  • Antibiotics
  • Immunosuppressants
  • Anti-arrhythmics

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Use of Therapeutic Drug Monitoring in traditional anticancer therapies
      • 3.2.2. The introduction of novel devices with marked technological advancements facilitates rapid throughput operations
    • 3.3. Market Challenges
      • 3.3.1. Operational barriers faced in conducting TDM tests
    • 3.4. Market Trends
      • 3.4.1. Upsurging demand for Personalized medicine and advanced technologies such as assay performance and drug monitoring
      • 3.4.2. Increasing Number of organ transplant procedures
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Therapeutic Drug Monitoring, by Type, Application, Therapeutic Areas, Technology, Class of drugs and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Therapeutic Drug Monitoring (Value)
      • 5.2.1. Global Therapeutic Drug Monitoring by: Type (Value)
        • 5.2.1.1. Consumable
        • 5.2.1.2. Equipment [Immunoassay analyzer]
      • 5.2.2. Global Therapeutic Drug Monitoring by: Application (Value)
        • 5.2.2.1. Hospitals (Clinical Pharmacology departments)
        • 5.2.2.2. Pathological labs
        • 5.2.2.3. Research and Academic Institutions
        • 5.2.2.4. Pharmaceutical and Biotech firms
      • 5.2.3. Global Therapeutic Drug Monitoring by: Therapeutic Areas (Value)
        • 5.2.3.1. Alimentary Tract
        • 5.2.3.2. Hematological Disease
        • 5.2.3.3. Others
      • 5.2.4. Global Therapeutic Drug Monitoring by: Technology (Value)
        • 5.2.4.1. Fluorescence Immunoassay
        • 5.2.4.2. Radioimmunoassay
        • 5.2.4.3. GCMS
      • 5.2.5. Global Therapeutic Drug Monitoring by: Class of drugs (Value)
        • 5.2.5.1. Anti-epileptics
        • 5.2.5.2. Antibiotics
        • 5.2.5.3. Immunosuppressants
        • 5.2.5.4. Anti-arrhythmics
      • 5.2.6. Global Therapeutic Drug Monitoring Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
  • 6. Therapeutic Drug Monitoring: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Abbott Laboratories (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Hoffmann-La Roche (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Siemens Healthineers (Germany)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Thermo Fisher Scientific (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Danaher Corporation (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Bio-Rad Laboratories (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Biomérieux (France)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Bühlmann Laboratories (Switzerland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Sekisui Medical (Japan)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Randox Laboratories (United Kingdom)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Therapeutic Drug Monitoring Sale, by Type, Application, Therapeutic Areas, Technology, Class of drugs and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Therapeutic Drug Monitoring (Value)
      • 7.2.1. Global Therapeutic Drug Monitoring by: Type (Value)
        • 7.2.1.1. Consumable
        • 7.2.1.2. Equipment [Immunoassay analyzer]
      • 7.2.2. Global Therapeutic Drug Monitoring by: Application (Value)
        • 7.2.2.1. Hospitals (Clinical Pharmacology departments)
        • 7.2.2.2. Pathological labs
        • 7.2.2.3. Research and Academic Institutions
        • 7.2.2.4. Pharmaceutical and Biotech firms
      • 7.2.3. Global Therapeutic Drug Monitoring by: Therapeutic Areas (Value)
        • 7.2.3.1. Alimentary Tract
        • 7.2.3.2. Hematological Disease
        • 7.2.3.3. Others
      • 7.2.4. Global Therapeutic Drug Monitoring by: Technology (Value)
        • 7.2.4.1. Fluorescence Immunoassay
        • 7.2.4.2. Radioimmunoassay
        • 7.2.4.3. GCMS
      • 7.2.5. Global Therapeutic Drug Monitoring by: Class of drugs (Value)
        • 7.2.5.1. Anti-epileptics
        • 7.2.5.2. Antibiotics
        • 7.2.5.3. Immunosuppressants
        • 7.2.5.4. Anti-arrhythmics
      • 7.2.6. Global Therapeutic Drug Monitoring Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Therapeutic Drug Monitoring: by Type(USD Million)
  • Table 2. Therapeutic Drug Monitoring Consumable , by Region USD Million (2018-2023)
  • Table 3. Therapeutic Drug Monitoring Equipment [Immunoassay analyzer] , by Region USD Million (2018-2023)
  • Table 4. Therapeutic Drug Monitoring: by Application(USD Million)
  • Table 5. Therapeutic Drug Monitoring Hospitals (Clinical Pharmacology departments) , by Region USD Million (2018-2023)
  • Table 6. Therapeutic Drug Monitoring Pathological labs , by Region USD Million (2018-2023)
  • Table 7. Therapeutic Drug Monitoring Research and Academic Institutions , by Region USD Million (2018-2023)
  • Table 8. Therapeutic Drug Monitoring Pharmaceutical and Biotech firms , by Region USD Million (2018-2023)
  • Table 9. Therapeutic Drug Monitoring: by Therapeutic Areas(USD Million)
  • Table 10. Therapeutic Drug Monitoring Alimentary Tract , by Region USD Million (2018-2023)
  • Table 11. Therapeutic Drug Monitoring Hematological Disease , by Region USD Million (2018-2023)
  • Table 12. Therapeutic Drug Monitoring Others , by Region USD Million (2018-2023)
  • Table 13. Therapeutic Drug Monitoring: by Technology(USD Million)
  • Table 14. Therapeutic Drug Monitoring Fluorescence Immunoassay , by Region USD Million (2018-2023)
  • Table 15. Therapeutic Drug Monitoring Radioimmunoassay , by Region USD Million (2018-2023)
  • Table 16. Therapeutic Drug Monitoring GCMS , by Region USD Million (2018-2023)
  • Table 17. Therapeutic Drug Monitoring: by Class of drugs(USD Million)
  • Table 18. Therapeutic Drug Monitoring Anti-epileptics , by Region USD Million (2018-2023)
  • Table 19. Therapeutic Drug Monitoring Antibiotics , by Region USD Million (2018-2023)
  • Table 20. Therapeutic Drug Monitoring Immunosuppressants , by Region USD Million (2018-2023)
  • Table 21. Therapeutic Drug Monitoring Anti-arrhythmics , by Region USD Million (2018-2023)
  • Table 22. South America Therapeutic Drug Monitoring, by Country USD Million (2018-2023)
  • Table 23. South America Therapeutic Drug Monitoring, by Type USD Million (2018-2023)
  • Table 24. South America Therapeutic Drug Monitoring, by Application USD Million (2018-2023)
  • Table 25. South America Therapeutic Drug Monitoring, by Therapeutic Areas USD Million (2018-2023)
  • Table 26. South America Therapeutic Drug Monitoring, by Technology USD Million (2018-2023)
  • Table 27. South America Therapeutic Drug Monitoring, by Class of drugs USD Million (2018-2023)
  • Table 28. Brazil Therapeutic Drug Monitoring, by Type USD Million (2018-2023)
  • Table 29. Brazil Therapeutic Drug Monitoring, by Application USD Million (2018-2023)
  • Table 30. Brazil Therapeutic Drug Monitoring, by Therapeutic Areas USD Million (2018-2023)
  • Table 31. Brazil Therapeutic Drug Monitoring, by Technology USD Million (2018-2023)
  • Table 32. Brazil Therapeutic Drug Monitoring, by Class of drugs USD Million (2018-2023)
  • Table 33. Argentina Therapeutic Drug Monitoring, by Type USD Million (2018-2023)
  • Table 34. Argentina Therapeutic Drug Monitoring, by Application USD Million (2018-2023)
  • Table 35. Argentina Therapeutic Drug Monitoring, by Therapeutic Areas USD Million (2018-2023)
  • Table 36. Argentina Therapeutic Drug Monitoring, by Technology USD Million (2018-2023)
  • Table 37. Argentina Therapeutic Drug Monitoring, by Class of drugs USD Million (2018-2023)
  • Table 38. Rest of South America Therapeutic Drug Monitoring, by Type USD Million (2018-2023)
  • Table 39. Rest of South America Therapeutic Drug Monitoring, by Application USD Million (2018-2023)
  • Table 40. Rest of South America Therapeutic Drug Monitoring, by Therapeutic Areas USD Million (2018-2023)
  • Table 41. Rest of South America Therapeutic Drug Monitoring, by Technology USD Million (2018-2023)
  • Table 42. Rest of South America Therapeutic Drug Monitoring, by Class of drugs USD Million (2018-2023)
  • Table 43. Asia Pacific Therapeutic Drug Monitoring, by Country USD Million (2018-2023)
  • Table 44. Asia Pacific Therapeutic Drug Monitoring, by Type USD Million (2018-2023)
  • Table 45. Asia Pacific Therapeutic Drug Monitoring, by Application USD Million (2018-2023)
  • Table 46. Asia Pacific Therapeutic Drug Monitoring, by Therapeutic Areas USD Million (2018-2023)
  • Table 47. Asia Pacific Therapeutic Drug Monitoring, by Technology USD Million (2018-2023)
  • Table 48. Asia Pacific Therapeutic Drug Monitoring, by Class of drugs USD Million (2018-2023)
  • Table 49. China Therapeutic Drug Monitoring, by Type USD Million (2018-2023)
  • Table 50. China Therapeutic Drug Monitoring, by Application USD Million (2018-2023)
  • Table 51. China Therapeutic Drug Monitoring, by Therapeutic Areas USD Million (2018-2023)
  • Table 52. China Therapeutic Drug Monitoring, by Technology USD Million (2018-2023)
  • Table 53. China Therapeutic Drug Monitoring, by Class of drugs USD Million (2018-2023)
  • Table 54. Japan Therapeutic Drug Monitoring, by Type USD Million (2018-2023)
  • Table 55. Japan Therapeutic Drug Monitoring, by Application USD Million (2018-2023)
  • Table 56. Japan Therapeutic Drug Monitoring, by Therapeutic Areas USD Million (2018-2023)
  • Table 57. Japan Therapeutic Drug Monitoring, by Technology USD Million (2018-2023)
  • Table 58. Japan Therapeutic Drug Monitoring, by Class of drugs USD Million (2018-2023)
  • Table 59. India Therapeutic Drug Monitoring, by Type USD Million (2018-2023)
  • Table 60. India Therapeutic Drug Monitoring, by Application USD Million (2018-2023)
  • Table 61. India Therapeutic Drug Monitoring, by Therapeutic Areas USD Million (2018-2023)
  • Table 62. India Therapeutic Drug Monitoring, by Technology USD Million (2018-2023)
  • Table 63. India Therapeutic Drug Monitoring, by Class of drugs USD Million (2018-2023)
  • Table 64. South Korea Therapeutic Drug Monitoring, by Type USD Million (2018-2023)
  • Table 65. South Korea Therapeutic Drug Monitoring, by Application USD Million (2018-2023)
  • Table 66. South Korea Therapeutic Drug Monitoring, by Therapeutic Areas USD Million (2018-2023)
  • Table 67. South Korea Therapeutic Drug Monitoring, by Technology USD Million (2018-2023)
  • Table 68. South Korea Therapeutic Drug Monitoring, by Class of drugs USD Million (2018-2023)
  • Table 69. Taiwan Therapeutic Drug Monitoring, by Type USD Million (2018-2023)
  • Table 70. Taiwan Therapeutic Drug Monitoring, by Application USD Million (2018-2023)
  • Table 71. Taiwan Therapeutic Drug Monitoring, by Therapeutic Areas USD Million (2018-2023)
  • Table 72. Taiwan Therapeutic Drug Monitoring, by Technology USD Million (2018-2023)
  • Table 73. Taiwan Therapeutic Drug Monitoring, by Class of drugs USD Million (2018-2023)
  • Table 74. Australia Therapeutic Drug Monitoring, by Type USD Million (2018-2023)
  • Table 75. Australia Therapeutic Drug Monitoring, by Application USD Million (2018-2023)
  • Table 76. Australia Therapeutic Drug Monitoring, by Therapeutic Areas USD Million (2018-2023)
  • Table 77. Australia Therapeutic Drug Monitoring, by Technology USD Million (2018-2023)
  • Table 78. Australia Therapeutic Drug Monitoring, by Class of drugs USD Million (2018-2023)
  • Table 79. Rest of Asia-Pacific Therapeutic Drug Monitoring, by Type USD Million (2018-2023)
  • Table 80. Rest of Asia-Pacific Therapeutic Drug Monitoring, by Application USD Million (2018-2023)
  • Table 81. Rest of Asia-Pacific Therapeutic Drug Monitoring, by Therapeutic Areas USD Million (2018-2023)
  • Table 82. Rest of Asia-Pacific Therapeutic Drug Monitoring, by Technology USD Million (2018-2023)
  • Table 83. Rest of Asia-Pacific Therapeutic Drug Monitoring, by Class of drugs USD Million (2018-2023)
  • Table 84. Europe Therapeutic Drug Monitoring, by Country USD Million (2018-2023)
  • Table 85. Europe Therapeutic Drug Monitoring, by Type USD Million (2018-2023)
  • Table 86. Europe Therapeutic Drug Monitoring, by Application USD Million (2018-2023)
  • Table 87. Europe Therapeutic Drug Monitoring, by Therapeutic Areas USD Million (2018-2023)
  • Table 88. Europe Therapeutic Drug Monitoring, by Technology USD Million (2018-2023)
  • Table 89. Europe Therapeutic Drug Monitoring, by Class of drugs USD Million (2018-2023)
  • Table 90. Germany Therapeutic Drug Monitoring, by Type USD Million (2018-2023)
  • Table 91. Germany Therapeutic Drug Monitoring, by Application USD Million (2018-2023)
  • Table 92. Germany Therapeutic Drug Monitoring, by Therapeutic Areas USD Million (2018-2023)
  • Table 93. Germany Therapeutic Drug Monitoring, by Technology USD Million (2018-2023)
  • Table 94. Germany Therapeutic Drug Monitoring, by Class of drugs USD Million (2018-2023)
  • Table 95. France Therapeutic Drug Monitoring, by Type USD Million (2018-2023)
  • Table 96. France Therapeutic Drug Monitoring, by Application USD Million (2018-2023)
  • Table 97. France Therapeutic Drug Monitoring, by Therapeutic Areas USD Million (2018-2023)
  • Table 98. France Therapeutic Drug Monitoring, by Technology USD Million (2018-2023)
  • Table 99. France Therapeutic Drug Monitoring, by Class of drugs USD Million (2018-2023)
  • Table 100. Italy Therapeutic Drug Monitoring, by Type USD Million (2018-2023)
  • Table 101. Italy Therapeutic Drug Monitoring, by Application USD Million (2018-2023)
  • Table 102. Italy Therapeutic Drug Monitoring, by Therapeutic Areas USD Million (2018-2023)
  • Table 103. Italy Therapeutic Drug Monitoring, by Technology USD Million (2018-2023)
  • Table 104. Italy Therapeutic Drug Monitoring, by Class of drugs USD Million (2018-2023)
  • Table 105. United Kingdom Therapeutic Drug Monitoring, by Type USD Million (2018-2023)
  • Table 106. United Kingdom Therapeutic Drug Monitoring, by Application USD Million (2018-2023)
  • Table 107. United Kingdom Therapeutic Drug Monitoring, by Therapeutic Areas USD Million (2018-2023)
  • Table 108. United Kingdom Therapeutic Drug Monitoring, by Technology USD Million (2018-2023)
  • Table 109. United Kingdom Therapeutic Drug Monitoring, by Class of drugs USD Million (2018-2023)
  • Table 110. Netherlands Therapeutic Drug Monitoring, by Type USD Million (2018-2023)
  • Table 111. Netherlands Therapeutic Drug Monitoring, by Application USD Million (2018-2023)
  • Table 112. Netherlands Therapeutic Drug Monitoring, by Therapeutic Areas USD Million (2018-2023)
  • Table 113. Netherlands Therapeutic Drug Monitoring, by Technology USD Million (2018-2023)
  • Table 114. Netherlands Therapeutic Drug Monitoring, by Class of drugs USD Million (2018-2023)
  • Table 115. Rest of Europe Therapeutic Drug Monitoring, by Type USD Million (2018-2023)
  • Table 116. Rest of Europe Therapeutic Drug Monitoring, by Application USD Million (2018-2023)
  • Table 117. Rest of Europe Therapeutic Drug Monitoring, by Therapeutic Areas USD Million (2018-2023)
  • Table 118. Rest of Europe Therapeutic Drug Monitoring, by Technology USD Million (2018-2023)
  • Table 119. Rest of Europe Therapeutic Drug Monitoring, by Class of drugs USD Million (2018-2023)
  • Table 120. MEA Therapeutic Drug Monitoring, by Country USD Million (2018-2023)
  • Table 121. MEA Therapeutic Drug Monitoring, by Type USD Million (2018-2023)
  • Table 122. MEA Therapeutic Drug Monitoring, by Application USD Million (2018-2023)
  • Table 123. MEA Therapeutic Drug Monitoring, by Therapeutic Areas USD Million (2018-2023)
  • Table 124. MEA Therapeutic Drug Monitoring, by Technology USD Million (2018-2023)
  • Table 125. MEA Therapeutic Drug Monitoring, by Class of drugs USD Million (2018-2023)
  • Table 126. Middle East Therapeutic Drug Monitoring, by Type USD Million (2018-2023)
  • Table 127. Middle East Therapeutic Drug Monitoring, by Application USD Million (2018-2023)
  • Table 128. Middle East Therapeutic Drug Monitoring, by Therapeutic Areas USD Million (2018-2023)
  • Table 129. Middle East Therapeutic Drug Monitoring, by Technology USD Million (2018-2023)
  • Table 130. Middle East Therapeutic Drug Monitoring, by Class of drugs USD Million (2018-2023)
  • Table 131. Africa Therapeutic Drug Monitoring, by Type USD Million (2018-2023)
  • Table 132. Africa Therapeutic Drug Monitoring, by Application USD Million (2018-2023)
  • Table 133. Africa Therapeutic Drug Monitoring, by Therapeutic Areas USD Million (2018-2023)
  • Table 134. Africa Therapeutic Drug Monitoring, by Technology USD Million (2018-2023)
  • Table 135. Africa Therapeutic Drug Monitoring, by Class of drugs USD Million (2018-2023)
  • Table 136. North America Therapeutic Drug Monitoring, by Country USD Million (2018-2023)
  • Table 137. North America Therapeutic Drug Monitoring, by Type USD Million (2018-2023)
  • Table 138. North America Therapeutic Drug Monitoring, by Application USD Million (2018-2023)
  • Table 139. North America Therapeutic Drug Monitoring, by Therapeutic Areas USD Million (2018-2023)
  • Table 140. North America Therapeutic Drug Monitoring, by Technology USD Million (2018-2023)
  • Table 141. North America Therapeutic Drug Monitoring, by Class of drugs USD Million (2018-2023)
  • Table 142. United States Therapeutic Drug Monitoring, by Type USD Million (2018-2023)
  • Table 143. United States Therapeutic Drug Monitoring, by Application USD Million (2018-2023)
  • Table 144. United States Therapeutic Drug Monitoring, by Therapeutic Areas USD Million (2018-2023)
  • Table 145. United States Therapeutic Drug Monitoring, by Technology USD Million (2018-2023)
  • Table 146. United States Therapeutic Drug Monitoring, by Class of drugs USD Million (2018-2023)
  • Table 147. Canada Therapeutic Drug Monitoring, by Type USD Million (2018-2023)
  • Table 148. Canada Therapeutic Drug Monitoring, by Application USD Million (2018-2023)
  • Table 149. Canada Therapeutic Drug Monitoring, by Therapeutic Areas USD Million (2018-2023)
  • Table 150. Canada Therapeutic Drug Monitoring, by Technology USD Million (2018-2023)
  • Table 151. Canada Therapeutic Drug Monitoring, by Class of drugs USD Million (2018-2023)
  • Table 152. Mexico Therapeutic Drug Monitoring, by Type USD Million (2018-2023)
  • Table 153. Mexico Therapeutic Drug Monitoring, by Application USD Million (2018-2023)
  • Table 154. Mexico Therapeutic Drug Monitoring, by Therapeutic Areas USD Million (2018-2023)
  • Table 155. Mexico Therapeutic Drug Monitoring, by Technology USD Million (2018-2023)
  • Table 156. Mexico Therapeutic Drug Monitoring, by Class of drugs USD Million (2018-2023)
  • Table 157. Company Basic Information, Sales Area and Its Competitors
  • Table 158. Company Basic Information, Sales Area and Its Competitors
  • Table 159. Company Basic Information, Sales Area and Its Competitors
  • Table 160. Company Basic Information, Sales Area and Its Competitors
  • Table 161. Company Basic Information, Sales Area and Its Competitors
  • Table 162. Company Basic Information, Sales Area and Its Competitors
  • Table 163. Company Basic Information, Sales Area and Its Competitors
  • Table 164. Company Basic Information, Sales Area and Its Competitors
  • Table 165. Company Basic Information, Sales Area and Its Competitors
  • Table 166. Company Basic Information, Sales Area and Its Competitors
  • Table 167. Therapeutic Drug Monitoring: by Type(USD Million)
  • Table 168. Therapeutic Drug Monitoring Consumable , by Region USD Million (2025-2030)
  • Table 169. Therapeutic Drug Monitoring Equipment [Immunoassay analyzer] , by Region USD Million (2025-2030)
  • Table 170. Therapeutic Drug Monitoring: by Application(USD Million)
  • Table 171. Therapeutic Drug Monitoring Hospitals (Clinical Pharmacology departments) , by Region USD Million (2025-2030)
  • Table 172. Therapeutic Drug Monitoring Pathological labs , by Region USD Million (2025-2030)
  • Table 173. Therapeutic Drug Monitoring Research and Academic Institutions , by Region USD Million (2025-2030)
  • Table 174. Therapeutic Drug Monitoring Pharmaceutical and Biotech firms , by Region USD Million (2025-2030)
  • Table 175. Therapeutic Drug Monitoring: by Therapeutic Areas(USD Million)
  • Table 176. Therapeutic Drug Monitoring Alimentary Tract , by Region USD Million (2025-2030)
  • Table 177. Therapeutic Drug Monitoring Hematological Disease , by Region USD Million (2025-2030)
  • Table 178. Therapeutic Drug Monitoring Others , by Region USD Million (2025-2030)
  • Table 179. Therapeutic Drug Monitoring: by Technology(USD Million)
  • Table 180. Therapeutic Drug Monitoring Fluorescence Immunoassay , by Region USD Million (2025-2030)
  • Table 181. Therapeutic Drug Monitoring Radioimmunoassay , by Region USD Million (2025-2030)
  • Table 182. Therapeutic Drug Monitoring GCMS , by Region USD Million (2025-2030)
  • Table 183. Therapeutic Drug Monitoring: by Class of drugs(USD Million)
  • Table 184. Therapeutic Drug Monitoring Anti-epileptics , by Region USD Million (2025-2030)
  • Table 185. Therapeutic Drug Monitoring Antibiotics , by Region USD Million (2025-2030)
  • Table 186. Therapeutic Drug Monitoring Immunosuppressants , by Region USD Million (2025-2030)
  • Table 187. Therapeutic Drug Monitoring Anti-arrhythmics , by Region USD Million (2025-2030)
  • Table 188. South America Therapeutic Drug Monitoring, by Country USD Million (2025-2030)
  • Table 189. South America Therapeutic Drug Monitoring, by Type USD Million (2025-2030)
  • Table 190. South America Therapeutic Drug Monitoring, by Application USD Million (2025-2030)
  • Table 191. South America Therapeutic Drug Monitoring, by Therapeutic Areas USD Million (2025-2030)
  • Table 192. South America Therapeutic Drug Monitoring, by Technology USD Million (2025-2030)
  • Table 193. South America Therapeutic Drug Monitoring, by Class of drugs USD Million (2025-2030)
  • Table 194. Brazil Therapeutic Drug Monitoring, by Type USD Million (2025-2030)
  • Table 195. Brazil Therapeutic Drug Monitoring, by Application USD Million (2025-2030)
  • Table 196. Brazil Therapeutic Drug Monitoring, by Therapeutic Areas USD Million (2025-2030)
  • Table 197. Brazil Therapeutic Drug Monitoring, by Technology USD Million (2025-2030)
  • Table 198. Brazil Therapeutic Drug Monitoring, by Class of drugs USD Million (2025-2030)
  • Table 199. Argentina Therapeutic Drug Monitoring, by Type USD Million (2025-2030)
  • Table 200. Argentina Therapeutic Drug Monitoring, by Application USD Million (2025-2030)
  • Table 201. Argentina Therapeutic Drug Monitoring, by Therapeutic Areas USD Million (2025-2030)
  • Table 202. Argentina Therapeutic Drug Monitoring, by Technology USD Million (2025-2030)
  • Table 203. Argentina Therapeutic Drug Monitoring, by Class of drugs USD Million (2025-2030)
  • Table 204. Rest of South America Therapeutic Drug Monitoring, by Type USD Million (2025-2030)
  • Table 205. Rest of South America Therapeutic Drug Monitoring, by Application USD Million (2025-2030)
  • Table 206. Rest of South America Therapeutic Drug Monitoring, by Therapeutic Areas USD Million (2025-2030)
  • Table 207. Rest of South America Therapeutic Drug Monitoring, by Technology USD Million (2025-2030)
  • Table 208. Rest of South America Therapeutic Drug Monitoring, by Class of drugs USD Million (2025-2030)
  • Table 209. Asia Pacific Therapeutic Drug Monitoring, by Country USD Million (2025-2030)
  • Table 210. Asia Pacific Therapeutic Drug Monitoring, by Type USD Million (2025-2030)
  • Table 211. Asia Pacific Therapeutic Drug Monitoring, by Application USD Million (2025-2030)
  • Table 212. Asia Pacific Therapeutic Drug Monitoring, by Therapeutic Areas USD Million (2025-2030)
  • Table 213. Asia Pacific Therapeutic Drug Monitoring, by Technology USD Million (2025-2030)
  • Table 214. Asia Pacific Therapeutic Drug Monitoring, by Class of drugs USD Million (2025-2030)
  • Table 215. China Therapeutic Drug Monitoring, by Type USD Million (2025-2030)
  • Table 216. China Therapeutic Drug Monitoring, by Application USD Million (2025-2030)
  • Table 217. China Therapeutic Drug Monitoring, by Therapeutic Areas USD Million (2025-2030)
  • Table 218. China Therapeutic Drug Monitoring, by Technology USD Million (2025-2030)
  • Table 219. China Therapeutic Drug Monitoring, by Class of drugs USD Million (2025-2030)
  • Table 220. Japan Therapeutic Drug Monitoring, by Type USD Million (2025-2030)
  • Table 221. Japan Therapeutic Drug Monitoring, by Application USD Million (2025-2030)
  • Table 222. Japan Therapeutic Drug Monitoring, by Therapeutic Areas USD Million (2025-2030)
  • Table 223. Japan Therapeutic Drug Monitoring, by Technology USD Million (2025-2030)
  • Table 224. Japan Therapeutic Drug Monitoring, by Class of drugs USD Million (2025-2030)
  • Table 225. India Therapeutic Drug Monitoring, by Type USD Million (2025-2030)
  • Table 226. India Therapeutic Drug Monitoring, by Application USD Million (2025-2030)
  • Table 227. India Therapeutic Drug Monitoring, by Therapeutic Areas USD Million (2025-2030)
  • Table 228. India Therapeutic Drug Monitoring, by Technology USD Million (2025-2030)
  • Table 229. India Therapeutic Drug Monitoring, by Class of drugs USD Million (2025-2030)
  • Table 230. South Korea Therapeutic Drug Monitoring, by Type USD Million (2025-2030)
  • Table 231. South Korea Therapeutic Drug Monitoring, by Application USD Million (2025-2030)
  • Table 232. South Korea Therapeutic Drug Monitoring, by Therapeutic Areas USD Million (2025-2030)
  • Table 233. South Korea Therapeutic Drug Monitoring, by Technology USD Million (2025-2030)
  • Table 234. South Korea Therapeutic Drug Monitoring, by Class of drugs USD Million (2025-2030)
  • Table 235. Taiwan Therapeutic Drug Monitoring, by Type USD Million (2025-2030)
  • Table 236. Taiwan Therapeutic Drug Monitoring, by Application USD Million (2025-2030)
  • Table 237. Taiwan Therapeutic Drug Monitoring, by Therapeutic Areas USD Million (2025-2030)
  • Table 238. Taiwan Therapeutic Drug Monitoring, by Technology USD Million (2025-2030)
  • Table 239. Taiwan Therapeutic Drug Monitoring, by Class of drugs USD Million (2025-2030)
  • Table 240. Australia Therapeutic Drug Monitoring, by Type USD Million (2025-2030)
  • Table 241. Australia Therapeutic Drug Monitoring, by Application USD Million (2025-2030)
  • Table 242. Australia Therapeutic Drug Monitoring, by Therapeutic Areas USD Million (2025-2030)
  • Table 243. Australia Therapeutic Drug Monitoring, by Technology USD Million (2025-2030)
  • Table 244. Australia Therapeutic Drug Monitoring, by Class of drugs USD Million (2025-2030)
  • Table 245. Rest of Asia-Pacific Therapeutic Drug Monitoring, by Type USD Million (2025-2030)
  • Table 246. Rest of Asia-Pacific Therapeutic Drug Monitoring, by Application USD Million (2025-2030)
  • Table 247. Rest of Asia-Pacific Therapeutic Drug Monitoring, by Therapeutic Areas USD Million (2025-2030)
  • Table 248. Rest of Asia-Pacific Therapeutic Drug Monitoring, by Technology USD Million (2025-2030)
  • Table 249. Rest of Asia-Pacific Therapeutic Drug Monitoring, by Class of drugs USD Million (2025-2030)
  • Table 250. Europe Therapeutic Drug Monitoring, by Country USD Million (2025-2030)
  • Table 251. Europe Therapeutic Drug Monitoring, by Type USD Million (2025-2030)
  • Table 252. Europe Therapeutic Drug Monitoring, by Application USD Million (2025-2030)
  • Table 253. Europe Therapeutic Drug Monitoring, by Therapeutic Areas USD Million (2025-2030)
  • Table 254. Europe Therapeutic Drug Monitoring, by Technology USD Million (2025-2030)
  • Table 255. Europe Therapeutic Drug Monitoring, by Class of drugs USD Million (2025-2030)
  • Table 256. Germany Therapeutic Drug Monitoring, by Type USD Million (2025-2030)
  • Table 257. Germany Therapeutic Drug Monitoring, by Application USD Million (2025-2030)
  • Table 258. Germany Therapeutic Drug Monitoring, by Therapeutic Areas USD Million (2025-2030)
  • Table 259. Germany Therapeutic Drug Monitoring, by Technology USD Million (2025-2030)
  • Table 260. Germany Therapeutic Drug Monitoring, by Class of drugs USD Million (2025-2030)
  • Table 261. France Therapeutic Drug Monitoring, by Type USD Million (2025-2030)
  • Table 262. France Therapeutic Drug Monitoring, by Application USD Million (2025-2030)
  • Table 263. France Therapeutic Drug Monitoring, by Therapeutic Areas USD Million (2025-2030)
  • Table 264. France Therapeutic Drug Monitoring, by Technology USD Million (2025-2030)
  • Table 265. France Therapeutic Drug Monitoring, by Class of drugs USD Million (2025-2030)
  • Table 266. Italy Therapeutic Drug Monitoring, by Type USD Million (2025-2030)
  • Table 267. Italy Therapeutic Drug Monitoring, by Application USD Million (2025-2030)
  • Table 268. Italy Therapeutic Drug Monitoring, by Therapeutic Areas USD Million (2025-2030)
  • Table 269. Italy Therapeutic Drug Monitoring, by Technology USD Million (2025-2030)
  • Table 270. Italy Therapeutic Drug Monitoring, by Class of drugs USD Million (2025-2030)
  • Table 271. United Kingdom Therapeutic Drug Monitoring, by Type USD Million (2025-2030)
  • Table 272. United Kingdom Therapeutic Drug Monitoring, by Application USD Million (2025-2030)
  • Table 273. United Kingdom Therapeutic Drug Monitoring, by Therapeutic Areas USD Million (2025-2030)
  • Table 274. United Kingdom Therapeutic Drug Monitoring, by Technology USD Million (2025-2030)
  • Table 275. United Kingdom Therapeutic Drug Monitoring, by Class of drugs USD Million (2025-2030)
  • Table 276. Netherlands Therapeutic Drug Monitoring, by Type USD Million (2025-2030)
  • Table 277. Netherlands Therapeutic Drug Monitoring, by Application USD Million (2025-2030)
  • Table 278. Netherlands Therapeutic Drug Monitoring, by Therapeutic Areas USD Million (2025-2030)
  • Table 279. Netherlands Therapeutic Drug Monitoring, by Technology USD Million (2025-2030)
  • Table 280. Netherlands Therapeutic Drug Monitoring, by Class of drugs USD Million (2025-2030)
  • Table 281. Rest of Europe Therapeutic Drug Monitoring, by Type USD Million (2025-2030)
  • Table 282. Rest of Europe Therapeutic Drug Monitoring, by Application USD Million (2025-2030)
  • Table 283. Rest of Europe Therapeutic Drug Monitoring, by Therapeutic Areas USD Million (2025-2030)
  • Table 284. Rest of Europe Therapeutic Drug Monitoring, by Technology USD Million (2025-2030)
  • Table 285. Rest of Europe Therapeutic Drug Monitoring, by Class of drugs USD Million (2025-2030)
  • Table 286. MEA Therapeutic Drug Monitoring, by Country USD Million (2025-2030)
  • Table 287. MEA Therapeutic Drug Monitoring, by Type USD Million (2025-2030)
  • Table 288. MEA Therapeutic Drug Monitoring, by Application USD Million (2025-2030)
  • Table 289. MEA Therapeutic Drug Monitoring, by Therapeutic Areas USD Million (2025-2030)
  • Table 290. MEA Therapeutic Drug Monitoring, by Technology USD Million (2025-2030)
  • Table 291. MEA Therapeutic Drug Monitoring, by Class of drugs USD Million (2025-2030)
  • Table 292. Middle East Therapeutic Drug Monitoring, by Type USD Million (2025-2030)
  • Table 293. Middle East Therapeutic Drug Monitoring, by Application USD Million (2025-2030)
  • Table 294. Middle East Therapeutic Drug Monitoring, by Therapeutic Areas USD Million (2025-2030)
  • Table 295. Middle East Therapeutic Drug Monitoring, by Technology USD Million (2025-2030)
  • Table 296. Middle East Therapeutic Drug Monitoring, by Class of drugs USD Million (2025-2030)
  • Table 297. Africa Therapeutic Drug Monitoring, by Type USD Million (2025-2030)
  • Table 298. Africa Therapeutic Drug Monitoring, by Application USD Million (2025-2030)
  • Table 299. Africa Therapeutic Drug Monitoring, by Therapeutic Areas USD Million (2025-2030)
  • Table 300. Africa Therapeutic Drug Monitoring, by Technology USD Million (2025-2030)
  • Table 301. Africa Therapeutic Drug Monitoring, by Class of drugs USD Million (2025-2030)
  • Table 302. North America Therapeutic Drug Monitoring, by Country USD Million (2025-2030)
  • Table 303. North America Therapeutic Drug Monitoring, by Type USD Million (2025-2030)
  • Table 304. North America Therapeutic Drug Monitoring, by Application USD Million (2025-2030)
  • Table 305. North America Therapeutic Drug Monitoring, by Therapeutic Areas USD Million (2025-2030)
  • Table 306. North America Therapeutic Drug Monitoring, by Technology USD Million (2025-2030)
  • Table 307. North America Therapeutic Drug Monitoring, by Class of drugs USD Million (2025-2030)
  • Table 308. United States Therapeutic Drug Monitoring, by Type USD Million (2025-2030)
  • Table 309. United States Therapeutic Drug Monitoring, by Application USD Million (2025-2030)
  • Table 310. United States Therapeutic Drug Monitoring, by Therapeutic Areas USD Million (2025-2030)
  • Table 311. United States Therapeutic Drug Monitoring, by Technology USD Million (2025-2030)
  • Table 312. United States Therapeutic Drug Monitoring, by Class of drugs USD Million (2025-2030)
  • Table 313. Canada Therapeutic Drug Monitoring, by Type USD Million (2025-2030)
  • Table 314. Canada Therapeutic Drug Monitoring, by Application USD Million (2025-2030)
  • Table 315. Canada Therapeutic Drug Monitoring, by Therapeutic Areas USD Million (2025-2030)
  • Table 316. Canada Therapeutic Drug Monitoring, by Technology USD Million (2025-2030)
  • Table 317. Canada Therapeutic Drug Monitoring, by Class of drugs USD Million (2025-2030)
  • Table 318. Mexico Therapeutic Drug Monitoring, by Type USD Million (2025-2030)
  • Table 319. Mexico Therapeutic Drug Monitoring, by Application USD Million (2025-2030)
  • Table 320. Mexico Therapeutic Drug Monitoring, by Therapeutic Areas USD Million (2025-2030)
  • Table 321. Mexico Therapeutic Drug Monitoring, by Technology USD Million (2025-2030)
  • Table 322. Mexico Therapeutic Drug Monitoring, by Class of drugs USD Million (2025-2030)
  • Table 323. Research Programs/Design for This Report
  • Table 324. Key Data Information from Secondary Sources
  • Table 325. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Therapeutic Drug Monitoring: by Type USD Million (2018-2023)
  • Figure 5. Global Therapeutic Drug Monitoring: by Application USD Million (2018-2023)
  • Figure 6. Global Therapeutic Drug Monitoring: by Therapeutic Areas USD Million (2018-2023)
  • Figure 7. Global Therapeutic Drug Monitoring: by Technology USD Million (2018-2023)
  • Figure 8. Global Therapeutic Drug Monitoring: by Class of drugs USD Million (2018-2023)
  • Figure 9. South America Therapeutic Drug Monitoring Share (%), by Country
  • Figure 10. Asia Pacific Therapeutic Drug Monitoring Share (%), by Country
  • Figure 11. Europe Therapeutic Drug Monitoring Share (%), by Country
  • Figure 12. MEA Therapeutic Drug Monitoring Share (%), by Country
  • Figure 13. North America Therapeutic Drug Monitoring Share (%), by Country
  • Figure 14. Global Therapeutic Drug Monitoring share by Players 2023 (%)
  • Figure 15. Global Therapeutic Drug Monitoring share by Players (Top 3) 2023(%)
  • Figure 16. Global Therapeutic Drug Monitoring share by Players (Top 5) 2023(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 19. Abbott Laboratories (United States) Revenue: by Geography 2023
  • Figure 20. Hoffmann-La Roche (Switzerland) Revenue, Net Income and Gross profit
  • Figure 21. Hoffmann-La Roche (Switzerland) Revenue: by Geography 2023
  • Figure 22. Siemens Healthineers (Germany) Revenue, Net Income and Gross profit
  • Figure 23. Siemens Healthineers (Germany) Revenue: by Geography 2023
  • Figure 24. Thermo Fisher Scientific (United States) Revenue, Net Income and Gross profit
  • Figure 25. Thermo Fisher Scientific (United States) Revenue: by Geography 2023
  • Figure 26. Danaher Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 27. Danaher Corporation (United States) Revenue: by Geography 2023
  • Figure 28. Bio-Rad Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 29. Bio-Rad Laboratories (United States) Revenue: by Geography 2023
  • Figure 30. Biomérieux (France) Revenue, Net Income and Gross profit
  • Figure 31. Biomérieux (France) Revenue: by Geography 2023
  • Figure 32. Bühlmann Laboratories (Switzerland) Revenue, Net Income and Gross profit
  • Figure 33. Bühlmann Laboratories (Switzerland) Revenue: by Geography 2023
  • Figure 34. Sekisui Medical (Japan) Revenue, Net Income and Gross profit
  • Figure 35. Sekisui Medical (Japan) Revenue: by Geography 2023
  • Figure 36. Randox Laboratories (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 37. Randox Laboratories (United Kingdom) Revenue: by Geography 2023
  • Figure 38. Global Therapeutic Drug Monitoring: by Type USD Million (2025-2030)
  • Figure 39. Global Therapeutic Drug Monitoring: by Application USD Million (2025-2030)
  • Figure 40. Global Therapeutic Drug Monitoring: by Therapeutic Areas USD Million (2025-2030)
  • Figure 41. Global Therapeutic Drug Monitoring: by Technology USD Million (2025-2030)
  • Figure 42. Global Therapeutic Drug Monitoring: by Class of drugs USD Million (2025-2030)
  • Figure 43. South America Therapeutic Drug Monitoring Share (%), by Country
  • Figure 44. Asia Pacific Therapeutic Drug Monitoring Share (%), by Country
  • Figure 45. Europe Therapeutic Drug Monitoring Share (%), by Country
  • Figure 46. MEA Therapeutic Drug Monitoring Share (%), by Country
  • Figure 47. North America Therapeutic Drug Monitoring Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Abbott Laboratories (United States)
  • Hoffmann-La Roche (Switzerland)
  • Siemens Healthineers (Germany)
  • Thermo Fisher Scientific (United States)
  • Danaher Corporation (United States)
  • Bio-Rad Laboratories (United States)
  • Biomérieux (France)
  • Bühlmann Laboratories (Switzerland)
  • Sekisui Medical (Japan)
  • Randox Laboratories (United Kingdom)
Select User Access Type

Key Highlights of Report


Mar 2024 227 Pages 89 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Therapeutic Drug Monitoring Quantitative research analysis
Global Therapeutic Drug Monitoring Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Therapeutic Drug Monitoring market are Abbott Laboratories (United States), Hoffmann-La Roche (Switzerland), Siemens Healthineers (Germany), Thermo Fisher Scientific (United States), Danaher Corporation (United States), Bio-Rad Laboratories (United States), Biomérieux (France), Bühlmann Laboratories (Switzerland), Sekisui Medical (Japan) and Randox Laboratories (United Kingdom), to name a few.
North America is dominating the Therapeutic Drug Monitoring Market.
"Operational barriers faced in conducting TDM tests" is seen as one of the major challenges by many Industry Players of Therapeutic Drug Monitoring Market
The Therapeutic Drug Monitoring market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get complete companies available in our research coverage.
The Therapeutic Drug Monitoring market is expected to see a steady growth rate during projected year 2023 to 2030.

Know More About Global Therapeutic Drug Monitoring Report?

Have a Query? Click Here

Other Related Reports

Digital Therapeutics Comprehensive Study by Disease (Diabetes, Obesity, Cardiovascular Diseases (CVD), Central Nervous System (CNS) Disease, Gastrointestinal Disorders (GID), Respiratory Diseases, Sm...
$ 3650
Kidney Fibrosis Treatment Comprehensive Study by Therapeutics (Angiotensin Converting Enzyme (ACE) Inhibitors, Pirfenidone, Renin Inhibitors, Angiotensin II Receptor Blockers (ARBs), Vasopeptidase In...
$ 3350
Legionella Testing Comprehensive Study by Type (Microbial Culture, DFA Stain, PCR, Others), Application (Water Testing, IVD Testing), End User (Hospital and Clinic, Diagnostic Laboratory) Players and...
$ 3500
Chemotherapy Induced Peripheral Neuropathy Treatment Comprehensive Study by Type (APX-3330, BR-297, Cannabidiol, Dimiracetam, Others), Application (Platinum Agents, Taxanes, Vinca Alkaloids, Others) ...
$ 3500
Animal Therapeutics and Diagnostics Comprehensive Study by Type (Animal Diagnostics Products (Instruments, Consumables), Animal Therapeutics Products (Anti-Parasitic Drugs and Antibiotics, Anti-Infla...
$ 3750
Irritable Bowel Syndrome Treatment Comprehensive Study by Type (Lubiprostone, Linaclotide, Eluxadoline, Rifaximin, Ramosetron Hydrochloride, Others), Distribution Channel (Hospital Pharmacies, Online...
$ 3450